Trial Profile
Open-label study to assess efficacy and safety of a single dose (i.v.) of NMA78 in patients with Parkinson's Syndrome (PS) or Essential Tremor (ET) and healthy volunteers (HV)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Sep 2018
Price :
$35
*
At a glance
- Drugs NMA 78 (Primary)
- Indications Essential tremor; Parkinsonian disorders
- Focus Adverse reactions; Diagnostic use
- Sponsors Nihon Medi-Physics
- 03 Jun 2016 New trial record